Novel gene (TMEM230) linked to Parkinson’s disease by unknown
COMMENTARY Open Access
Novel gene (TMEM230) linked to
Parkinson’s disease
Diana A. Olszewska1*, Conor Fearon1,2 and Tim Lynch1
Abstract
Mutations in six genes are known to cause Parkinson’s disease (PD) (autosomal dominant: alpha-synuclein, LRRK2,
VPS35 and autosomal recessive: Parkin, PINK1 and DJ1) and number of other genes are implicated. In a recent
article Deng and colleagues studied a large four generation American family of European descent and linked
mutations in a novel gene, transmembrane-protein 230 gene (TMEM230) with lewy body confirmed PD. The
authors demonstrated that pathogenic TMEM230 variants in primary mouse neurons affected movement of
synaptic vesicles suggesting that TMEM230 may slow vesicular transport. Further experiments in HEK293 cells
(carrying the pathogenic TMEM230 variants) showed increased alpha-synuclein levels. This study indicated that
the impaired vesicular trafficking may contribute to the pathogenesis of PD. Understanding the various cellular
mechanisms leading to PD may lead to the development of novel, much needed therapeutic options. These
mechanisms could include: enhanced clearance of damaged mitochondria, development of kinase inhibitors,
VPS35/retromer function enhancers or now the possibility of vesicular transport modification.
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Background
The pathogenesis of Parkinson’s disease (PD) involves the
interaction of environmental and genetic factors. Although
mutations in known PD genes are responsible for only 10 %
of PD cases, the discovery of causative genes has improved
our understanding of this incurable disease. Mutations in six
genes are known to be causative of PD (autosomal domin-
ant: alpha-synuclein-SNCA, LRRK2, VPS35 and autosomal
recessive: Parkin, PINK1, DJ1) and number of other genes
are implicated (EIF4G1, DNAJC13). The diagnosis of PD
can only be confirmed pathologically by the loss of dopa-
minergic neurons in the substantia nigra pars compacta ac-
companied by the presence of Lewy bodies (LB) and Lewy
neurites. Of note LB are absent in Parkin-associated PD [1].
Novel gene TMEM230 linked with Parkinson’s disease in a
large family study
Deng and colleagues, [2] recently, linked mutations in a
novel gene, trans-membrane protein 230 gene (TMEM230),
with LB-confirmed PD. The authors studied a large, four
generation American family of mixed European descent
(Dutch/German/Russian) with autosomal dominant PD.
They used genome-wide linkage analysis in 13 affected
family members to localise the candidate region at the short
arm of chromosome 20 (10.7 Mb with 141 known genes).
Subsequently, samples from four distant affected relatives
and one healthy family member (age 87) were selected for
whole-exome sequencing. Following the exclusion of
variants with an average heterozygosity of more than 0.01
and filtering for variants resulting in functional change, a
missense variant in TMEM230 (c.422G >T) was identified
in four affected only. Co-segregation with the disease was
confirmed by Sanger sequencing in other affected family
members only (DNA analysis was performed in 65 family
members including 13 with PD). This new gene variant was
not present in the dbSNP database, 1000 Genomes Project
database, Exome Sequencing Project database or 1238 con-
trols. Individuals with c.422G >T variant had PD symptoms,
a good levodopa response and mean age-at-onset 67 (range:
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48–85). Two further non-significant variants in intronic
regions were detected.
Neuropathological examination
The neuropathological examination in three affected PD
patients carrying TMEM230 c.422G > T variant con-
firmed the presence of LB and Lewy neurities in midbrain
and neocortex.
New variants in TMEM230
Further sequencing of 832 North American PD samples
found two variants: c.275A-G in a 34-year-old man with
PD and his unaffected mother (age 57) and c.551A-G in a
33- year-old affected man with a family history of PD in
his maternal male cousin (disease onset at age 35 with no
further information available). The pathogenicity of these
two variants remains elusive. Sequencing of 574 Chinese
PD samples led to the detection of a new c.550_552delTA-
GinsCCCGGG variant in 7 probands with familial PD,
confirmed by a segregation analysis in two families. This
variant was found in 7 (31 %) of 225 familial PD, but was
not found in 10000 Chinese controls.
Previous reports on the family
This is not the first time this Dutch/German/Russian
family has been studied. Villarino-Guell and colleagues
[1] previously reported a novel missense variant in
DNAJC13 gene in the same family; however it did not
fully co-segregate with the disease. The variant was ab-
sent in three PD patients and present in a healthy
87 year-old. Villarino-Guell et al. postulated that indeed
the DNAJC13 variant may not be the sole cause of the
disease [1].
TMEM230 involvement in vesicular transport
Deng et al. [2] very nicely demonstrated that all four
described pathogenic variants in primary mouse neurons
adversely affected movement of synaptic vesicles suggest-
ing that TMEM230 mutations slow vesicular trafficking.
Co-localization with SNCA was also observed. Impaired
vesicular transport and neurotransmitter release could
lead to a failure of SNCA degradation and accummulation
of SNCA in cells. Experiments in HEK293 cells carrying
these variants demonstrated an increase in SNCA levels
compared with controls. Impaired trafficking and recyc-
ling of vesicles could be a new causative mechanism in the
pathogenesis of PD.
Cellular mechanisms in Parkinson’s disease and their role
in therapeutics
Understanding the various cellular mechanisms leading
to PD may lead to the development of novel, much
needed therapeutic options. These mechanisms could
include: enhanced clearance of damaged mitochondria,
development of kinase inhibitors, VPS35/retromer func-
tion enhancers or now the possibility of vesicular trans-
port modification. It is well recognized that mutations in
PINK1 and Parkin cause defects in mitochondrial
homeostasis and accumulation of damaged mitochondria
lead to neurodegeneration [3]. Parkin has housekeeping
duties and development of Parkin enhancers leading to
increased clearance of damaged mitochondria may have
an important role in therapeutics [3]. Protein and lipid
kinases are crucial in metabolism, cell signaling, and
protein regulation. G2019S is the most common muta-
tion in Leucine-rich repeat kinase 2 (LRRK2) and it may
cause kinase activity up-regulation, proinflammatory
response enhancement, and neuron toxicity [4, 5]. It was
recently demonstrated that a novel kinase inhibitor
(PF-06447475) attenuated α-synuclein-induced neurode-
generation in wild-type rats providing another hopeful
therapeutic mechanism [4, 5]. Another PD gene VPS35 is
a central scaffold for binding of other subunits of the ret-
romer. The retromer is crucial in mediating retrograde
transport of specific membrane proteins from endosomes
back to the trans-Golgi network (hydrolases and proteases)
and to the cell surface [6]. The retromer has an important
role in secretion of signaling proteins (Wnt) and apoptotic
cell clearance [6]. Absence of retromer activity causes de-
creased Wnt secretion and dopaminergic neuronal loss.
Enhancement of intracellular transport occurs with an
increase in the VPS35 level leading to modulation of
retromer function [6]. As the enhancement of the retromer
function reverses the neurotoxic effects without any
obvious toxicity, the development of VPS35/retromer
enhancers could be another therapeutic possibility [6].
VPS35 is linked to the trans Golgi network and possibly
has a common pathway with newly described TMEM230;
however, this has to be yet determined.
Conclusions
The interplay between the gene products is important
and the novel mechanism mediated by TMEM230 adds
to current knowledge and may lead to targeting the
modification of a vesicle trafficking as a novel thera-
peutic option.
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